|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MN frequency in the lymphocytes of patients with acromegaly increased with elevated serum IGF-1 levels (p<0.05), whereas the number of NPBs and the frequency of apoptotic cells decreased with elevated serum IGF-1 levels (p<0.01 and p<0.05 respectively).
|
24382376 |
2014 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This lack of association may suggest that tear IGF-1 levels might not have an effect on CCT or IOP findings in patients with acromegaly.
|
28127733 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a disease of exaggerated somatic growth and distorted proportion arising from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
|
20234189 |
2010 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cabergoline monotherapy is reported to normalize IGF-I levels in more than one-third of patients with acromegaly.
|
28025719 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The paradoxical GH response reflected the clinical characteristics, especially IGF-I level, glucose metabolism, and drug efficacy in acromegaly.
|
30476255 |
2019 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While current treatment modalities have greatly improved prognoses for most patients, a significant number present clinical symptoms of acromegaly with elevated levels of IGF-1 in the absence of increased GH levels, a phenomenon known as micromegaly.
|
31071497 |
2020 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Control of acromegaly was defined as a random serum growth hormone (GH) < 1 ng/mL and an age-normalised serum insulin-like growth factor-I (IGF-I) value.
|
28879646 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<b>Purpose:</b> Excess growth hormone (GH) secretion in acromegaly patients results in increased levels of IGF-1 expression, which causes the clinical manifestations of acromegaly.
|
30619084 |
2018 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred acromegaly patients on medical therapy (mean age = 47.1 years; SD = 11.96) completed an online preference study evaluating hypothetical patient profiles described in terms of insulin-like growth factor-I (IGF-I) levels, tumor size, comorbid conditions, signs/symptoms, and quality of life (QoL).
|
30627944 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Background Biochemical control of GH/IGF-I excess in acromegaly (ACRO) is associated with persistent impairment of trabecular microstructure leading to increased risk of vertebral fractures.
|
30640713 |
2019 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although the normalisation of GH and IGF1 levels is the main objective in all patients with acromegaly, GH and IGF1 levels may be discordant, especially during somatostatin analogue therapy.
|
24144967 |
2014 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An uncontrolled hyperactive GH-IGF-1 axis may play a dominant role in the development of PTC rather than the BRAFV600E mutation in patients with acromegaly.
|
25329702 |
2014 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A phase III trial of oral octreotide capsules demonstrated that this treatment can safely sustain suppressed levels of GH and IGF-1 and reduce the severity of symptoms in patients with acromegaly previously controlled by injectable SRL therapy, with the added benefit of no injection-site reactions.
|
26610414 |
2016 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data indicates that tissue-level properties of cortical bone are significantly altered in patients with controlled acromegaly after reversal of long-term exposure to pathologically high GH and IGF-1 levels.
|
28077497 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
GH, IGF-1, and Age Are Important Contributors to Thyroid Abnormalities in Patients with Acromegaly.
|
29593792 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I.
|
28168377 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A univariate analysis was conducted and eight features, including age, hypertension, ophthalmic disorders, GH, IGF-1, nadir GH, maximal tumor diameter, and Knosp grade, were significantly associated with the TSS response in patients with acromegaly.
|
31673954 |
2020 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Included in this prospective cohort were 41 patients with acromegaly who underwent surgery alone and achieved postoperative normalization of insulin-like growth factor-1.
|
27681883 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, a GH-receptor blocking agent, pegvisomant, was licensed for use in acromegaly and appears to normalise IGF-1 in almost all patients.
|
16262568 |
2005 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, routine screening of GD should be considered in women with acromegaly, particularly in those with risk factors for GD and with uncontrolled IGF-1 levels before pregnancy.
|
31520541 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Significant correlation could be detected between insulin-like growth factor 1 (IGF-1) index and peak superior LA-CS (r = .49, P = .05) in acromegaly.
|
29569265 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is characterized by an excess of growth hormone (GH) and insulin like growth-factor 1 (IGF1).
|
31751301 |
2019 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
530 patients (36%) reported at least 1 acral enlargement symptom and were tested for IGF-1, 41 were above range, persisted in 7, and among those, 2 cases of acromegaly were diagnosed (prevalence of at least 1.35 cases/1000).
|
28898247 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To evaluate the response of bone to chronic long-term growth hormone (GH) and insulin-like growth factor-1 (IGF1) excess by measuring the expression of selected mRNA and microRNA (miR) in bone tissue samples of patients with active acromegaly.
|
29374071 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A low secretory activity of these tumours might explain the normal plasma values for GH and insulin-like growth factor 1 (IGF1) and the absence of clinical signs of acromegaly.
|
27913611 |
2017 |